Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 47

1.

A Comparison of the Adaptive Immune Response between Recovered Anthrax Patients and Individuals Receiving Three Different Anthrax Vaccines.

Laws TR, Kuchuloria T, Chitadze N, Little SF, Webster WM, Debes AK, Saginadze S, Tsertsvadze N, Chubinidze M, Rivard RG, Tsanava S, Dyson EH, Simpson AJ, Hepburn MJ, Trapaidze N.

PLoS One. 2016 Mar 23;11(3):e0148713. doi: 10.1371/journal.pone.0148713. eCollection 2016.

2.

Structural and immunological analysis of anthrax recombinant protective antigen adsorbed to aluminum hydroxide adjuvant.

Wagner L, Verma A, Meade BD, Reiter K, Narum DL, Brady RA, Little SF, Burns DL.

Clin Vaccine Immunol. 2012 Sep;19(9):1465-73. doi: 10.1128/CVI.00174-12. Epub 2012 Jul 18.

3.

Analysis of defined combinations of monoclonal antibodies in anthrax toxin neutralization assays and their synergistic action.

Ngundi MM, Meade BD, Little SF, Quinn CP, Corbett CR, Brady RA, Burns DL.

Clin Vaccine Immunol. 2012 May;19(5):731-9. doi: 10.1128/CVI.05714-11. Epub 2012 Mar 21.

4.

Antigenic profiling of yersinia pestis infection in the Wyoming coyote (Canis latrans).

Vernati G, Edwards WH, Rocke TE, Little SF, Andrews GP.

J Wildl Dis. 2011 Jan;47(1):21-9.

PMID:
21269993
5.

Monoclonal antibodies directed against protective antigen of Bacillus anthracis enhance lethal toxin activity in vivo.

Little SF, Webster WM, Fisher DE.

FEMS Immunol Med Microbiol. 2011 Jun;62(1):11-22. doi: 10.1111/j.1574-695X.2011.00782.x. Epub 2011 Feb 2.

6.

Quantitative anti-F1 and anti-V IgG ELISAs as serological correlates of protection against plague in female Swiss Webster mice.

Little SF, Webster WM, Wilhelm H, Fisher D, Norris SL, Powell BS, Enama J, Adamovicz JJ.

Vaccine. 2010 Jan 22;28(4):934-9. doi: 10.1016/j.vaccine.2009.10.143. Epub 2009 Nov 17.

PMID:
19925906
7.

Comparative performance of a licensed anthrax vaccine versus electroporation based delivery of a PA encoding DNA vaccine in rhesus macaques.

Livingston BD, Little SF, Luxembourg A, Ellefsen B, Hannaman D.

Vaccine. 2010 Jan 22;28(4):1056-61. doi: 10.1016/j.vaccine.2009.10.111. Epub 2009 Nov 5.

PMID:
19896452
8.

Advances in the development of next-generation anthrax vaccines.

Friedlander AM, Little SF.

Vaccine. 2009 Nov 5;27 Suppl 4:D28-32. doi: 10.1016/j.vaccine.2009.08.102. Review.

PMID:
19837282
9.

An in vivo passive protection assay for the evaluation of immunity in AVA-vaccinated individuals.

Hewetson JF, Little SF, Ivins BE, Johnson WM, Pittman PR, Brown JE, Norris SL, Nielsen CJ.

Vaccine. 2008 Aug 5;26(33):4262-6. doi: 10.1016/j.vaccine.2008.05.068. Epub 2008 Jun 12.

PMID:
18586363
10.

Evaluation of quantitative anti-F1 IgG and anti-V IgG ELISAs for use as an in vitro-based potency assay of plague vaccine in mice.

Little SF, Webster WM, Wilhelm H, Powell B, Enama J, Adamovicz JJ.

Biologicals. 2008 Sep;36(5):287-95. doi: 10.1016/j.biologicals.2008.03.001. Epub 2008 May 16.

PMID:
18485733
11.

Effect of aluminum hydroxide adjuvant and formaldehyde in the formulation of rPA anthrax vaccine.

Little SF, Ivins BE, Webster WM, Norris SL, Andrews GP.

Vaccine. 2007 Apr 12;25(15):2771-7. Epub 2007 Jan 2.

PMID:
17240008
12.

Prophylaxis and therapy of inhalational anthrax by a novel monoclonal antibody to protective antigen that mimics vaccine-induced immunity.

Vitale L, Blanset D, Lowy I, O'Neill T, Goldstein J, Little SF, Andrews GP, Dorough G, Taylor RK, Keler T.

Infect Immun. 2006 Oct;74(10):5840-7.

13.

Low doses of antigen coupled to anti-CR2 mAbs induce rapid and enduring IgG immune responses in mice and in cynomolgus monkeys.

Whipple EC, Ditto AH, Shanahan RS, Gatesman JJ, Little SF, Taylor RP, Lindorfer MA.

Mol Immunol. 2007 Jan;44(4):377-88. Epub 2006 May 2.

PMID:
16631928
14.

Comparative vaccine efficacy of different isoforms of recombinant protective antigen against Bacillus anthracis spore challenge in rabbits.

Ribot WJ, Powell BS, Ivins BE, Little SF, Johnson WM, Hoover TA, Norris SL, Adamovicz JJ, Friedlander AM, Andrews GP.

Vaccine. 2006 Apr 24;24(17):3469-76. Epub 2006 Feb 21.

PMID:
16519970
15.

Duration of protection of rabbits after vaccination with Bacillus anthracis recombinant protective antigen vaccine.

Little SF, Ivins BE, Webster WM, Fellows PF, Pitt ML, Norris SL, Andrews GP.

Vaccine. 2006 Mar 24;24(14):2530-6. Epub 2005 Dec 27.

PMID:
16417950
16.
17.

Anthrax vaccines: a development update.

Little SF.

BioDrugs. 2005;19(4):233-45. Review.

PMID:
16128606
18.

Anthrax biosensor, protective antigen ion channel asymmetric blockade.

Halverson KM, Panchal RG, Nguyen TL, Gussio R, Little SF, Misakian M, Bavari S, Kasianowicz JJ.

J Biol Chem. 2005 Oct 7;280(40):34056-62. Epub 2005 Aug 8.

19.

Anthrax capsule vaccine protects against experimental infection.

Chabot DJ, Scorpio A, Tobery SA, Little SF, Norris SL, Friedlander AM.

Vaccine. 2004 Nov 15;23(1):43-7.

PMID:
15519706
20.

Evaluation of an anti-rPA IgG ELISA for measuring the antibody response in mice.

Little SF, Webster WM, Norris SL, Andrews GP.

Biologicals. 2004 Jun;32(2):62-9.

PMID:
15454183
21.

CpG oligonucleotides improve the protective immune response induced by the anthrax vaccination of rhesus macaques.

Klinman DM, Xie H, Little SF, Currie D, Ivins BE.

Vaccine. 2004 Jul 29;22(21-22):2881-6.

PMID:
15246624
22.

Development of an in vitro-based potency assay for anthrax vaccine.

Little SF, Webster WM, Ivins BE, Fellows PF, Norris SL, Andrews GP.

Vaccine. 2004 Jul 29;22(21-22):2843-52.

PMID:
15246620
23.
24.
25.

Defining a serological correlate of protection in rabbits for a recombinant anthrax vaccine.

Little SF, Ivins BE, Fellows PF, Pitt ML, Norris SL, Andrews GP.

Vaccine. 2004 Jan 2;22(3-4):422-30.

PMID:
14670324
26.

Evaluation of the compatibility of a second generation recombinant anthrax vaccine with aluminum-containing adjuvants.

Jendrek S, Little SF, Hem S, Mitra G, Giardina S.

Vaccine. 2003 Jun 20;21(21-22):3011-8.

PMID:
12798645
27.
28.

Anthrax vaccine efficacy in golden Syrian hamsters.

Fellows PF, Linscott MK, Little SF, Gibbs P, Ivins BE.

Vaccine. 2002 Jan 31;20(9-10):1421-4.

PMID:
11818161
29.

In vitro correlate of immunity in a rabbit model of inhalational anthrax.

Pitt ML, Little SF, Ivins BE, Fellows P, Barth J, Hewetson J, Gibbs P, Dertzbaugh M, Friedlander AM.

Vaccine. 2001 Sep 14;19(32):4768-73.

PMID:
11535328
30.

Macrophage-derived cell lines do not express proinflammatory cytokines after exposure to Bacillus anthracis lethal toxin.

Erwin JL, DaSilva LM, Bavari S, Little SF, Friedlander AM, Chanh TC.

Infect Immun. 2001 Feb;69(2):1175-7.

31.

Molecular pathogenesis of Bacillus anthracis infection.

Little SF, Ivins BE.

Microbes Infect. 1999 Feb;1(2):131-9. Review.

PMID:
10594977
32.

Comparative efficacy of experimental anthrax vaccine candidates against inhalation anthrax in rhesus macaques.

Ivins BE, Pitt ML, Fellows PF, Farchaus JW, Benner GE, Waag DM, Little SF, Anderson GW Jr, Gibbs PH, Friedlander AM.

Vaccine. 1998 Jul;16(11-12):1141-8.

PMID:
9682372
33.
34.

Passive protection by polyclonal antibodies against Bacillus anthracis infection in guinea pigs.

Little SF, Ivins BE, Fellows PF, Friedlander AM.

Infect Immun. 1997 Dec;65(12):5171-5.

35.

Characterization of lethal factor binding and cell receptor binding domains of protective antigen of Bacillus anthracis using monoclonal antibodies.

Little SF, Novak JM, Lowe JR, Leppla SH, Singh Y, Klimpel KR, Lidgerding BC, Friedlander AM.

Microbiology. 1996 Mar;142 ( Pt 3):707-15.

PMID:
8868446
36.

Structure-function analysis of Bacillus anthracis edema factor by using monoclonal antibodies.

Little SF, Leppla SH, Burnett JW, Friedlander AM.

Biochem Biophys Res Commun. 1994 Mar 15;199(2):676-82.

PMID:
8135809
37.

Functional characterization of protease-treated Bacillus anthracis protective antigen.

Novak JM, Stein MP, Little SF, Leppla SH, Friedlander AM.

J Biol Chem. 1992 Aug 25;267(24):17186-93.

38.

Immunization against anthrax with Bacillus anthracis protective antigen combined with adjuvants.

Ivins BE, Welkos SL, Little SF, Crumrine MH, Nelson GO.

Infect Immun. 1992 Feb;60(2):662-8.

39.

Location of receptor-binding region of protective antigen from Bacillus anthracis.

Little SF, Lowe JR.

Biochem Biophys Res Commun. 1991 Oct 31;180(2):531-7.

PMID:
1953724
40.
41.

Identification of Bacillus anthracis by using monoclonal antibody to cell wall galactose-N-acetylglucosamine polysaccharide.

Ezzell JW Jr, Abshire TG, Little SF, Lidgerding BC, Brown C.

J Clin Microbiol. 1990 Feb;28(2):223-31.

43.
44.

Separation of three exotoxic factors of Bacillus anthracis by sequential immunosorbent chromatography.

Larson DK, Calton GJ, Little SF, Leppla SH, Burnett JW.

Toxicon. 1988;26(10):913-21.

PMID:
3144059
46.

Treatment of tularemia, including pulmonary tularemia, with gentamicin.

Mason WL, Eigelsbach HT, Little SF, Bates JH.

Am Rev Respir Dis. 1980 Jan;121(1):39-45.

PMID:
7352712
47.

Immunologic protection against the Legionnaires' disease bacterium in the AKR/J mouse.

Hedlund KW, McGann VG, Copeland DS, Little SF, Allen RG.

Ann Intern Med. 1979 Apr;90(4):676-9.

PMID:
434655

Supplemental Content

Loading ...
Support Center